PHASE II COHORT B: RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Clinical trials for PHASE II COHORT B: RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.

Never miss a new study

Get alerted when new PHASE II COHORT B: RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA trials appear

Sign up with your email to follow new studies for PHASE II COHORT B: RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug trial offers hope for Tough-to-Treat blood cancers

Disease control Ongoing

This study is testing a drug called acalabrutinib in Chinese adults whose blood cancers have returned or not responded to previous treatments. The main goals are to check the drug's safety, how the body processes it, and whether it helps control cancers like mantle cell lymphoma …

Matched conditions: PHASE II COHORT B: RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

PHASE II COHORT B: RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Get alerted when new PHASE II COHORT B: RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA trials appear

New drug trial offers hope for Tough-to-Treat blood cancers